Ranbaxy Bows To Sweeping Penalties From US

Law360, New York (January 26, 2012, 1:21 PM EST) -- The U.S. government on Wednesday sought court approval of a consent decree that will hold generic drug maker Ranbaxy Laboratories Ltd. to unprecedented standards before it can again produce drugs for the U.S. market at four plants cited by the U.S. Food and Drug Administration for serious manufacturing violations.

The U.S. Department of Justice filed the consent decree for permanent injunction in Maryland federal court on behalf of the FDA about a month after Ranbaxy, India's largest pharmaceutical company, said it would set aside $500 million...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.